CN Patent

CN118240844B — 带状疱疹mRNA疫苗及其制备方法和应用

Assigned to Hangzhou Tianlong Pharmaceutical Co Ltd · Expires 2024-12-13 · 1y expired

What this patent protects

本发明属于mRNA疫苗技术领域，尤其涉及带状疱疹mRNA疫苗及其制备方法和应用。本发明提供的带状疱疹mRNA疫苗，含编码水痘‑带状疱疹病毒gE糖蛋白或其变体的RNA。所述疫苗能预防带状疱疹感染及其并发症。

USPTO Abstract

本发明属于mRNA疫苗技术领域，尤其涉及带状疱疹mRNA疫苗及其制备方法和应用。本发明提供的带状疱疹mRNA疫苗，含编码水痘‑带状疱疹病毒gE糖蛋白或其变体的RNA。所述疫苗能预防带状疱疹感染及其并发症。

Drugs covered by this patent

Patent Metadata

Patent number
CN118240844B
Jurisdiction
CN
Classification
—
Expires
2024-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Tianlong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.